 SHANGHAI and SAN FRANCISCO, Nov. 10, 2020 GLOBE NEWSWIRE -- Zai Lab Limiteds NASDAQ: ZLAB; HKEX: 9688 partner Five Prime Therapeutics, Inc. NASDAQ: FPRX, a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced positive topline results from the global, randomized, double-blind, placebo-controlled Phase 2 FIGHT trial. The trial compared bemarituzumab FPA144, a potential first-in-class targeted therapy, in combination with mFOLFOX6 chemotherapy to placebo in combination with mFOLFOX6 in patients with fibroblast growth factor receptor 2b-positive FGFR2b, HER2-negative front-line advanced gastric or gastroesophageal junction GEJ cancer. 